OTCMKTS:PMCB PharmaCyte Biotech - PMCB Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding PharmaCyte Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.89 -0.01 (-0.34%) (As of 03/20/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.87▼$2.9950-Day Range$2.85▼$3.0152-Week Range$1.85▼$3.10Volume15,209 shsAverage Volume38,888 shsMarket Capitalization$50.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort Interest About PharmaCyte Biotech (OTCMKTS:PMCB) StockPharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.Read More Receive PMCB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address PMCB Stock News HeadlinesFebruary 2, 2023 | msn.comA 45-year-old biotech CEO may have reduced his biological age by at least 5 years through a rigorous medical program that can cost up to $2 million a year, Bloomberg reportedFebruary 2, 2023 | finance.yahoo.comPharmaCyte Biotech to Implement Second $10-Million Share Repurchase PlanMarch 21, 2023 | Press Research (Ad)Stocks For Smart InvestorsThis under-the-radar stock is in the right industry at the perfect time.October 7, 2022 | seekingalpha.comPharmaCyte to evaluate opportunities; CEO steps downOctober 7, 2022 | markets.businessinsider.comPharmaCyte Names Joshua Silverman Interim CEO As CEO Kenneth Waggoner Steps DownAugust 15, 2022 | finance.yahoo.comPharmaCyte Biotech Reaches Cooperation Agreement with Iroquois CapitalJuly 28, 2022 | finance.yahoo.comIroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.July 21, 2022 | finance.yahoo.comPharmaCyte Biotech Commences First Phase of Two-Phase Pig StudyMarch 21, 2023 | PressReach (Ad)This Stock Has Room To RunAnalysts believe this stock's product demand could rise quickly in the next few years.July 11, 2022 | finance.yahoo.comIROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORSJuly 11, 2022 | finance.yahoo.comPharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022July 5, 2022 | finance.yahoo.comPharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap CellsJune 23, 2022 | finance.yahoo.comIROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETINGJune 15, 2022 | finance.yahoo.comPharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder ValueJune 13, 2022 | finance.yahoo.comPharmaCyte Biotech to Attend 2022 BIO International Convention in San DiegoJune 8, 2022 | finance.yahoo.comPharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder ValueApril 27, 2022 | finance.yahoo.comPharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for DiabetesApril 19, 2022 | marketwatch.comPharmaCyte Biotech Shares Reverse Course, Drop 8%April 19, 2022 | finance.yahoo.comPharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA RequirementsApril 13, 2022 | seekingalpha.comPharmaCyte gets on with preparations for pancreatic cancer trial amid FDA clinical holdApril 13, 2022 | finance.yahoo.comPharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical TrialApril 5, 2022 | finance.yahoo.comPharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of DirectorsMarch 22, 2022 | finance.yahoo.comPharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product CandidateMarch 18, 2022 | seekingalpha.comPharmaCyte Biotech reports Q3 resultsMarch 16, 2022 | finance.yahoo.comPharmaCyte Biotech Reports Third Quarter Financial Results and Operational HighlightsFebruary 22, 2022 | finance.yahoo.comPharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of IntegrationFebruary 14, 2022 | finance.yahoo.comPharmaCyte Biotech Updates Status of Investigational New Drug Application to FDASee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PMCB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address PMCB Company Calendar Last Earnings12/15/2021Today3/21/2023Fiscal Year End4/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:PMCB CUSIPN/A CIK1157075 Webwww.pharmacyte.com Phone(917) 595-2850Fax917-595-2851Employees4Year Founded1996Profitability EPS (Most Recent Fiscal Year)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-6.71% Return on Assets-6.64% Debt Debt-to-Equity RatioN/A Current Ratio87.95 Quick Ratio87.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.34 per share Price / Book0.67Miscellaneous Outstanding Shares17,440,000Free Float16,461,000Market Cap$50.40 million OptionableNot Optionable Beta-0.02 Social Links Key ExecutivesJoshua Nathaniel SilvermanChairman, President & Chief Executive OfficerCarlos A. TrujilloChief Financial OfficerJosé L. IglesiasChief Medical OfficerLilli BrandtnerDirector-Diabetes Program DevelopmentKey CompetitorsAptose BiosciencesNASDAQ:APTOAVROBIONASDAQ:AVROEiger BioPharmaceuticalsNASDAQ:EIGRTaysha Gene TherapiesNASDAQ:TSHAElevation OncologyNASDAQ:ELEVView All CompetitorsInstitutional OwnershipJane Street Group LLCBought 20,705 shares on 2/15/2023Ownership: 0.111%Belvedere Trading LLCBought 8,100 shares on 2/15/2023Ownership: 0.000%Susquehanna International Group LLPSold 35,900 shares on 2/14/2023Ownership: 0.000%Price T Rowe Associates Inc. MDSold 10,600 shares on 2/14/2023Ownership: 0.194%Charles Schwab Investment Management Inc.Bought 17,219 shares on 2/13/2023Ownership: 0.092%View All Institutional Transactions PMCB Stock - Frequently Asked Questions How have PMCB shares performed in 2023? PharmaCyte Biotech's stock was trading at $2.93 at the beginning of the year. Since then, PMCB stock has decreased by 1.4% and is now trading at $2.89. View the best growth stocks for 2023 here. How were PharmaCyte Biotech's earnings last quarter? PharmaCyte Biotech, Inc. (OTCMKTS:PMCB) posted its earnings results on Wednesday, December, 15th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. What other stocks do shareholders of PharmaCyte Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other PharmaCyte Biotech investors own include Co-Diagnostics (CODX), iBio (IBIO), Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), Vaxart (VXRT), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), OWC Pharmaceutical Research (OWCP), VBI Vaccines (VBIV) and Novavax (NVAX). What is PharmaCyte Biotech's stock symbol? PharmaCyte Biotech trades on the OTCMKTS under the ticker symbol "PMCB." Who are PharmaCyte Biotech's major shareholders? PharmaCyte Biotech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include K2 Principal Fund L.P. (3.91%), Simplex Trading LLC (0.00%), Susquehanna International Group LLP (0.00%), Price T Rowe Associates Inc. MD (0.19%), FNY Investment Advisers LLC (0.17%) and Jane Street Group LLC (0.11%). How do I buy shares of PharmaCyte Biotech? Shares of PMCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is PharmaCyte Biotech's stock price today? One share of PMCB stock can currently be purchased for approximately $2.89. How much money does PharmaCyte Biotech make? PharmaCyte Biotech (OTCMKTS:PMCB) has a market capitalization of $50.40 million. The company earns $-4,240,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. How can I contact PharmaCyte Biotech? PharmaCyte Biotech's mailing address is 23046 AVENIDA DE LA CARLOTA SUITE 600, LAGUNA HILLS CA, 92653. The official website for the company is www.pharmacyte.com. The company can be reached via phone at (917) 595-2850, via email at info@pharmacyte.com, or via fax at 917-595-2851. This page (OTCMKTS:PMCB) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.